N Chimanlal Enterprises Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: N Chimanlal Enterprises Pharmaceutical Export Portfolio Dataset — 5 Products, $16.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

N Chimanlal Enterprises — Pharmaceutical Exporter Profile (2026) | 5 Products, $16.6K Trade | TransData Nexus

N Chimanlal Enterprises

Indian Pharmaceutical Exporter · Brand Names & OTC Products Specialist · $16.6K Total Trade · DGFT Verified

N Chimanlal Enterprises is an Indian pharmaceutical exporter with a total trade value of $16.6K across 5 products in 1 therapeutic categories. Based on 99 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Betadine ($8.9K), Disprin ($2.6K), Neosporin ($2.4K).

N Chimanlal Enterprises — Export Portfolio & Destination Treemap

N Chimanlal Enterprises pharmaceutical export portfolio — 5 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is N Chimanlal Enterprises? — Company Overview & Market Position

Established in 1943, N Chimanlal Enterprises is a Mumbai-based export organization recognized by the Government of India, specifically the Ministry of Commerce & Industry. The company holds accreditations from Pharmexcil, FDA India, FPME, IMC, and FSSAI, reflecting its compliance with national standards. Over the decades, N Chimanlal Enterprises has built a strong reputation, establishing valuable connections with clients across Africa, Asia, the Caribbean, the Pacific, and Gulf countries.

The company operates under the Corporate Identification Number (CIN) U33110MH2005PTC158466, indicating its registration as a private limited entity in Mumbai, Maharashtra. While specific revenue figures are not publicly disclosed, N Chimanlal Enterprises has been recognized as a leading exporter in the pharmaceutical trade industry for over 75 years. The organization employs a dedicated team, with employee counts ranging from 11 to 50, as per available data. For more information, the company's official website is pilcare.com.

What Does N Chimanlal Enterprises Export? — Product Portfolio Analysis

Top Products by Export Value

1Betadine$8.9K 2

Product Portfolio — Top 5 by Export Value

N Chimanlal Enterprises exports 5 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Betadine	Brand Names & OTC Products	$8.9K	47	0.1%	13
2	Disprin	Brand Names & OTC Products	$2.6K	4	0.0%	4
3	Neosporin	Brand Names & OTC Products	$2.4K	20	2.4%	9
4	Crocin	Brand Names & OTC Products	$1.7K	19	2.0%	7
5	Combiflam	Brand Names & OTC Products	$1.0K	9	4.2%	5

N Chimanlal Enterprises exports 5 pharmaceutical products across 1 therapeutic categories with a total export value of $16.6K. The top category is Brand Names & OTC Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

N Chimanlal Enterprises — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

N Chimanlal Enterprises undertakes manufacturing operations, offering a portfolio of over 400 products across various therapeutic segments. This extensive range includes both branded and generic pharmaceuticals, catering to diverse healthcare needs. The company also exports its own brands, demonstrating its capability in product development and market expansion. While specific details about manufacturing plant locations and capacities are not publicly disclosed, N Chimanlal Enterprises emphasizes its commitment to quality and efficiency in its manufacturing processes.

3Key Leadership

Specific information regarding the CEO, CFO, and other key executives of N Chimanlal Enterprises is not publicly available. However, the company is known for its strong leadership and customer-focused approach, which have been instrumental in establishing valuable connections with clients across multiple continents. The leadership team is dedicated to upholding the company's values of financial discipline, integrity, and customer-centric operations, which have been ingrained in its employees, senior managers, and suppliers since its establishment in 1943.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does N Chimanlal Enterprises Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

N Chimanlal Enterprises has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company holds accreditations from Pharmexcil, FDA India, FPME, IMC, and FSSAI, reflecting its compliance with international standards. While specific regulatory filings, approvals, and market access statuses in these regions are not publicly disclosed, the company's extensive export portfolio and global clientele suggest a robust compliance framework and successful market penetration.

2Emerging Markets

N Chimanlal Enterprises has expanded its reach to emerging markets across Africa, Latin America, and Southeast Asia. The company's comprehensive export portfolio encompasses a wide range of products, identifying it as a primary supplier for pharmacies, hospitals, ministries of health, patients, and supermarkets. While specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly available, the company's global network and client base indicate a strong presence in these regions.

3Geographic Strategy

N Chimanlal Enterprises — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding N Chimanlal Enterprises' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's accreditations from FDA India and other regulatory bodies suggest a commitment to adhering to international standards and regulations. The absence of publicly disclosed FDA-specific information indicates that the company may not currently have direct FDA approvals or registrations.

2WHO & EU GMP

N Chimanlal Enterprises holds accreditations from Pharmexcil, FDA India, FPME, IMC, and FSSAI, reflecting its compliance with various international standards. However, specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The company's global clientele and extensive export portfolio suggest adherence to international quality standards, though specific certifications are not disclosed.

3CDSCO & Indian Regulatory

N Chimanlal Enterprises — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

N Chimanlal Enterprises operates in a competitive landscape with numerous pharmaceutical exporters globally. While specific competitors in overlapping categories are not publicly disclosed, the company's extensive product portfolio and global reach position it as a significant player in the pharmaceutical export sector. The company's focus on quality, customer-centric operations, and adherence to international standards contribute to its competitive edge in the market.

2Key Differentiators

N Chimanlal Enterprises' key differentiators include its extensive product portfolio, encompassing over 300,000 products across 23+ segments, and its global reach, exporting to over 37 countries across five continents. The company's commitment to quality, customer-focused approach, and adherence to international standards further distinguish it in the pharmaceutical export industry.

3Strategic Position

N Chimanlal Enterprises currently focuses on pharmaceutical exports, offering a comprehensive range of branded and generic pharmaceuticals, over-the-counter products, surgical items, and allied products. The company's strategic direction emphasizes expanding its global footprint while maintaining a strong presence in existing markets. Future outlooks suggest continued growth and resilience in the pharmaceutical export sector, leveraging its diversified product portfolio and international accreditations.

Buyer Due Diligence Brief — Evaluating N Chimanlal Enterprises as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

N Chimanlal Enterprises has a longstanding track record in the pharmaceutical export industry, with over 75 years of experience. The company has established valuable connections with clients across multiple continents, indicating reliability and consistency in its export volumes. While specific reliability indicators are not publicly disclosed, the company's accreditations from various regulatory bodies suggest a commitment to maintaining high standards of quality and compliance.

2Certifications to Verify

Importers should verify the following certifications when considering N Chimanlal Enterprises as a supplier:

FDA India Certification: Indicates compliance with Indian pharmaceutical manufacturing standards.

FPME Accreditation: Reflects adherence to pharmaceutical manufacturing and export standards.

IMC Membership: Demonstrates active participation in the Indian pharmaceutical industry.

Frequently Asked Questions — N Chimanlal Enterprises

How many pharmaceutical products does N Chimanlal Enterprises export from India?

N Chimanlal Enterprises exports 5 pharmaceutical products across 1 therapeutic categories. The top exports are Betadine ($8.9K), Disprin ($2.6K), Neosporin ($2.4K), Crocin ($1.7K), Combiflam ($1.0K). Total export value is $16.6K.

What is N Chimanlal Enterprises's total pharmaceutical export value?

N Chimanlal Enterprises's total pharmaceutical export value is $16.6K, based on 99 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does N Chimanlal Enterprises cover?

N Chimanlal Enterprises exports across 1 therapeutic categories. The largest are Brand Names & OTC Products (100.0%, 5 products).

Get Full N Chimanlal Enterprises Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.